Pulike Biological Engineering, Inc. (SHA:603566)
China · Delayed Price · Currency is CNY 10.74
-0.19 (-1.74%)
Jun 2, 2026, 3:00 PM CST
SHA:603566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,048 | 1,077 | 1,034 | 1,243 | 1,217 | 1,088 |
Other Revenue | 12.93 | 12.93 | 8.69 | 10.11 | 13.06 | 11.03 |
| 1,060 | 1,090 | 1,043 | 1,253 | 1,230 | 1,099 | |
Revenue Growth (YoY) | -2.32% | 4.54% | -16.77% | 1.84% | 11.97% | 18.32% |
Cost of Revenue | 437.52 | 437.35 | 405.63 | 488.4 | 459.74 | 379.95 |
Gross Profit | 622.98 | 652.53 | 636.93 | 764.3 | 770.33 | 718.62 |
Selling, General & Admin | 351.8 | 361.59 | 413.65 | 450.03 | 473.74 | 391.87 |
Research & Development | 98.76 | 99.65 | 106.05 | 101.1 | 92.62 | 85.57 |
Other Operating Expenses | 18.63 | 16.1 | 15.31 | 14.62 | 12.77 | 11.29 |
Operating Expenses | 468.22 | 473.79 | 529.74 | 593.41 | 594.47 | 496.51 |
Operating Income | 154.76 | 178.73 | 107.19 | 170.89 | 175.86 | 222.11 |
Interest Expense | -0.26 | -0.06 | -0.08 | -0.92 | -0.86 | - |
Interest & Investment Income | 6.09 | 4.96 | 4.8 | 21.79 | 10.09 | 2.5 |
Currency Exchange Gain (Loss) | -0.32 | -0.32 | 0.19 | 0.22 | 0.58 | -0.22 |
Other Non Operating Income (Expenses) | -0.72 | -0.4 | -0.78 | -0.73 | -0.65 | -0.56 |
EBT Excluding Unusual Items | 159.55 | 182.92 | 111.32 | 191.25 | 185.02 | 223.84 |
Gain (Loss) on Sale of Investments | 11.93 | 10.03 | -9.97 | -17.69 | -25.57 | 20.39 |
Gain (Loss) on Sale of Assets | -2 | -2.09 | -12.27 | -0.6 | -0.54 | -3.34 |
Asset Writedown | -1.19 | -0.8 | -1 | -0.03 | - | - |
Other Unusual Items | 21.85 | 17.29 | 10.7 | 21.68 | 18.81 | 43.28 |
Pretax Income | 190.15 | 207.34 | 98.76 | 194.61 | 177.72 | 284.18 |
Income Tax Expense | 22.41 | 22.34 | 5.96 | 20.1 | 9.9 | 40.04 |
Net Income | 172.82 | 184.99 | 92.81 | 174.52 | 167.82 | 244.14 |
Net Income to Common | 172.82 | 184.99 | 92.81 | 174.52 | 167.82 | 244.14 |
Net Income Growth | 45.95% | 99.33% | -46.82% | 3.99% | -31.26% | 7.20% |
Shares Outstanding (Basic) | 345 | 343 | 344 | 349 | 323 | 313 |
Shares Outstanding (Diluted) | 345 | 343 | 344 | 349 | 323 | 313 |
Shares Change (YoY) | 1.09% | -0.33% | -1.52% | 8.15% | 3.11% | -1.05% |
EPS (Basic) | 0.50 | 0.54 | 0.27 | 0.50 | 0.52 | 0.78 |
EPS (Diluted) | 0.50 | 0.54 | 0.27 | 0.50 | 0.52 | 0.78 |
EPS Growth | 44.38% | 100.00% | -46.00% | -3.85% | -33.33% | 8.33% |
Free Cash Flow | 200.36 | 281.3 | 147.73 | -22.2 | -128.8 | -105.01 |
Free Cash Flow Per Share | 0.58 | 0.82 | 0.43 | -0.06 | -0.40 | -0.34 |
Dividend Per Share | 0.600 | 0.600 | 0.400 | 0.700 | 0.350 | 0.200 |
Dividend Growth | 50.00% | 50.00% | -42.86% | 100.00% | 75.00% | -60.00% |
Gross Margin | 58.74% | 59.87% | 61.09% | 61.01% | 62.63% | 65.41% |
Operating Margin | 14.59% | 16.40% | 10.28% | 13.64% | 14.30% | 20.22% |
Profit Margin | 16.30% | 16.97% | 8.90% | 13.93% | 13.64% | 22.22% |
Free Cash Flow Margin | 18.89% | 25.81% | 14.17% | -1.77% | -10.47% | -9.56% |
EBITDA | 274.69 | 298.84 | 227.99 | 262.7 | 249.8 | 281.42 |
EBITDA Margin | 25.90% | 27.42% | 21.87% | 20.97% | 20.31% | 25.62% |
D&A For EBITDA | 119.94 | 120.11 | 120.79 | 91.81 | 73.93 | 59.31 |
EBIT | 154.76 | 178.73 | 107.19 | 170.89 | 175.86 | 222.11 |
EBIT Margin | 14.59% | 16.40% | 10.28% | 13.64% | 14.30% | 20.22% |
Effective Tax Rate | 11.78% | 10.78% | 6.03% | 10.33% | 5.57% | 14.09% |
Revenue as Reported | 1,060 | 1,090 | 1,043 | 1,253 | 1,230 | 1,099 |
Advertising Expenses | - | 27.42 | 10.27 | 5.54 | 7.62 | 7.54 |